These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 24883145)

  • 41. Aminoglycoside dosing in patients by kidney function and area under the curve: the Sawchuk-Zaske dosing method revisited in the era of obesity.
    Pai MP; Rodvold KA
    Diagn Microbiol Infect Dis; 2014 Feb; 78(2):178-87. PubMed ID: 24268292
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pediatric Obesity: Pharmacokinetics and Implications for Drug Dosing.
    Kendrick JG; Carr RR; Ensom MH
    Clin Ther; 2015 Sep; 37(9):1897-923. PubMed ID: 26361823
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Continuous arteriovenous hemofiltration of aminoglycoside antibiotics in critically ill patients.
    Zarowitz BJ; Anandan JV; Dumler F; Jayashankar J; Levin N
    J Clin Pharmacol; 1986; 26(8):686-9. PubMed ID: 3793961
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Reappraisal of guidelines for pharmacokinetic monitoring of aminoglycosides.
    Yee GC; Evans WE
    Pharmacotherapy; 1981; 1(1):55-75. PubMed ID: 6927603
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development of recommendations for dosing of commonly prescribed medications in critically ill obese children.
    Ross EL; Heizer J; Mixon MA; Jorgensen J; Valdez CA; Czaja AS; Reiter PD
    Am J Health Syst Pharm; 2015 Apr; 72(7):542-56. PubMed ID: 25788508
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides.
    Young DC; Zobell JT; Stockmann C; Waters CD; Ampofo K; Sherwin CM; Spigarelli MG
    Pediatr Pulmonol; 2013 Nov; 48(11):1047-61. PubMed ID: 24000183
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Once versus individualized multiple daily dosing of aminoglycosides in critically ill patients.
    Abdel-Bari A; Mokhtar MS; Sabry NA; El-Shafi SA; Bazan NS
    Saudi Pharm J; 2011 Jan; 19(1):9-17. PubMed ID: 23960738
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Influence of sepsis on higher daily dose of amikacin pharmacokinetics in critically ill patients.
    Mahmoudi L; Mohammadpour AH; Ahmadi A; Niknam R; Mojtahedzadeh M
    Eur Rev Med Pharmacol Sci; 2013 Feb; 17(3):285-91. PubMed ID: 23426530
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetic issues for antibiotics in the critically ill patient.
    Roberts JA; Lipman J
    Crit Care Med; 2009 Mar; 37(3):840-51; quiz 859. PubMed ID: 19237886
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients.
    Ulldemolins M; Roberts JA; Rello J; Paterson DL; Lipman J
    Clin Pharmacokinet; 2011 Feb; 50(2):99-110. PubMed ID: 21142293
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Drug dosing in the critically ill obese patient-a focus on sedation, analgesia, and delirium.
    Erstad BL; Barletta JF
    Crit Care; 2020 Jun; 24(1):315. PubMed ID: 32513237
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Assessment of aminoglycoside dosing and estimated glomerular filtration rate in determining gentamicin and tobramycin area under the curve and clearance.
    Lim AK; Mathanasenarajah G; Larmour I
    Intern Med J; 2015 Mar; 45(3):319-29. PubMed ID: 25581282
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Drug dosing in obese critically ill patients, a literature review.
    García-Díaz HC; Sánchez-Sancho P; Lalueza-Broto P; Nuvials X; Gorgas-Torner MQ; Doménech-Moral L
    Farm Hosp; 2024 Oct; ():. PubMed ID: 39419675
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of pharmacokinetic sampling methods on aminoglycoside dosing in critically ill surgery patients.
    Mann HJ; Wittbrodt ET; Baghaie AA; Cerra FB
    Pharmacotherapy; 1998; 18(2):371-8. PubMed ID: 9545157
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Choice of drug and dosage regimen. Two important risk factors for aminoglycoside nephrotoxicity.
    De Broe ME; Giuliano RA; Verpooten GA
    Am J Med; 1986 Jun; 80(6B):115-8. PubMed ID: 3728523
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of altered aminoglycoside volume of distribution on the adequacy of a three milligram per kilogram loading dose. Critical Care Research Group.
    Dorman T; Swoboda S; Zarfeshenfard F; Trentler B; Lipsett PA
    Surgery; 1998 Jul; 124(1):73-8. PubMed ID: 9663254
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Suboptimal aminoglycoside dosing in critically ill patients.
    Rea RS; Capitano B; Bies R; Bigos KL; Smith R; Lee H
    Ther Drug Monit; 2008 Dec; 30(6):674-81. PubMed ID: 19057371
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Systematic Review of Studies Reporting Antibiotic Pharmacokinetic Data in the Cerebrospinal Fluid of Critically Ill Patients with Uninflamed Meninges.
    Kumta N; Roberts JA; Lipman J; Wong WT; Joynt GM; Cotta MO
    Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33077649
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Altered aminoglycoside pharmacokinetics in the critically ill.
    Beckhouse MJ; Whyte IM; Byth PL; Napier JC; Smith AJ
    Anaesth Intensive Care; 1988 Nov; 16(4):418-22. PubMed ID: 3232800
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Aminoglycoside Allergic Reactions.
    Childs-Kean LM; Shaeer KM; Varghese Gupta S; Cho JC
    Pharmacy (Basel); 2019 Aug; 7(3):. PubMed ID: 31470509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.